Filing Flows

Filing Flows › Companies › NewAmsterdam Pharma Co N.V. › Cash flow

NewAmsterdam Pharma Co N.V. cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$40.0M in Q3 2026 · −$151M over twelve months

Operating cash flow−$39.8M
Capital spending−$177K
Free cash flow−$40.0M

Analysis

In Q3 2026, NewAmsterdam Pharma Co N.V. generated −$39.8M of operating cash flow and spent $177K on capital projects, leaving free cash flow of −$40.0M. That is $7.1M less than in Q3 2025 (−$32.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$150M; the largest uses were operating cash flow ($150M), other investing ($3.3M), capital spending ($395K); besides operations, cash came from shares issued ($39.3M), other financing ($2.0M); the cash balance fell by $115M.

Operating cash flow was −$39.8M against net income of −$17.4M. The largest differences: stock-based pay +$12.5M, accrued liabilities +$5.2M, deferred revenue +$2.9M.

Free cash flow

NewAmsterdam Pharma Co N.V.: free cash flow by quarterNewAmsterdam Pharma Co N.V.: free cash flow by quarter−$37.5MQ4 2024−$36.5MQ1 2025−$37.8MQ2 2025−$32.8MQ3 2025−$41.0MQ4 2025−$30.6MQ1 2026−$39.3MQ2 2026−$40.0MQ3 2026
Operating cash flow less capital spending.
NewAmsterdam Pharma Co N.V.: operating cash flow against capital spendingNewAmsterdam Pharma Co N.V.: operating cash flow against capital spendingOperating cash flowCapital spending−$37.5M$3KQ4 2024−$36.5M$16KQ1 2025−$37.7M$88KQ2 2025−$32.8M$42KQ3 2025−$40.9M$100KQ4 2025−$30.6M$38KQ1 2026−$39.2M$80KQ2 2026−$39.8M$177KQ3 2026
Latest (Q3 2026): Operating cash flow −$39.8M, Capital spending $177K.

Capital allocation, year by year

NewAmsterdam Pharma Co N.V.: where the cash came from (up) and went (down), by fiscal yearNewAmsterdam Pharma Co N.V.: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$29.5MFY2021: Capital spending −$24KFY2021FY2022: Operating cash flow $10.7MFY2022: Capital spending −$221K$10.7MFY2022FY2023: Operating cash flow −$141MFY2023: Shares issued $290KFY2023: Capital spending −$24K$290KFY2023FY2024: Operating cash flow −$159MFY2024: Shares issued $1.8MFY2024: Capital spending −$672K$1.8MFY2024FY2025: Operating cash flow −$148MFY2025: Shares issued $29.5MFY2025: Capital spending −$246K$29.5MFY2025
Over these 5 years operating cash flow totalled −$466M; the largest uses were operating cash flow ($477M) and capital spending ($1.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$628M
Debtnone
Net cash$628M
Cash runway4.2 years

NewAmsterdam Pharma Co N.V. is burning cash: its operations consume cash, a free cash flow of −$151M a year at the current rate against $628M of cash and investments: a runway of about 4.2 years before any new financing.

Where the cash came from and went

NewAmsterdam Pharma Co N.V.: sources (+) and uses (−) of cash, Q3 2026NewAmsterdam Pharma Co N.V.: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$39.8MOther investing$33.9MShares issued$5.5MCash drawn (+) / kept (−)$883KExchange rates−$260KCapital spending−$177KOther financing$1K
NewAmsterdam Pharma Co N.V.: sources (+) and uses (−) of cash, TTM to Q3 2026NewAmsterdam Pharma Co N.V.: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$150MCash drawn (+) / kept (−)$115MShares issued$39.3MOther investing−$3.3MExchange rates−$2.2MOther financing$2.0MCapital spending−$395K

From profit to cash

NewAmsterdam Pharma Co N.V.: net income to operating cash flow, Q3 2026NewAmsterdam Pharma Co N.V.: net income to operating cash flow, Q3 2026Net income−$17.4MDepreciation & amortization$67KStock-based pay$12.5MPayables−$835KAccrued liabilities$5.2MDeferred revenue$2.9MOperating cash flow−$39.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$39.8M−$177K$5.5M$883K−$40.0M
Q2 2026−$39.2M−$80K$10.9M$33.4M−$39.3M
Q1 2026−$30.6M−$38K$10.4M$32.4M−$30.6M
Q4 2025−$40.9M−$100K$12.5M$48.4M−$41.0M
Q3 2025−$32.8M−$42K$5.6M$24.1M−$32.8M
Q2 2025−$37.7M−$88K$3.4M$185M−$37.8M
Q1 2025−$36.5M−$16K$7.9M$23.3M−$36.5M
Q4 2024−$37.5M−$3K$1.3M−$349M−$37.5M

NewAmsterdam Pharma Co N.V.: income statement and cash flow

NewAmsterdam Pharma Co N.V., Q3 2026: revenue $19.2M (55× year over year), operating margin -230.6%. The chart follows the revenue to costs, profit and cash.

NewAmsterdam Pharma Co N.V.: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.